Clemente-Montaño CA, Morales-Cadena GM

Language: Spanish
References: 17
Page: 34-42
PDF size: 293.85 Kb.

ABSTRACT

Background: Epistaxis is one of the most common otorhinolaryngological emergencies, so it is important to know the factors that can modify its treatment and prognosis.
Objective: To study the characteristics of the population and observe if there is an association with the behavior of epistaxis.
Materials and Methods: Observational, longitudinal, retrospective study including patients who required hospitalization for epistaxis in a third level private care hospital in Mexico City from January 2016 to November 2019. Age, sex, personal pathological history, examination, laboratories, use of medications, treatment, recurrence and time of stay were analyzed, in search of associations.
Results: A significant association was found between the posterior location of the epistaxis with the need for definitive surgical treatment for adequate control of the epistaxis and a significant association of systemic arterial hypertension at the time of the evaluation, use of antiplatelet agents and cauterization as only treatment with risk of recurrence of epistaxis.
Conclusions: There are risk factors associated with more invasive treatments and a greater recurrence.

REFERENCES

1. Sauter TC, Hegazy K, Hautz WE, Krummrey G, et al. Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clin Otolaryngol 2018; 43 (1): 103-8. doi. 10.1111/coa.12904.

2. Gokdogan O, Akyildiz I, Sayin BY, Okutucu S, et al. The rate of epistaxis incidence in new-generation anticoagulants and perioperative approach in otorhinolaryngological practices. J Craniofac Surg 2017; 28 (2): e178-e182. doi. 10.1097/SCS.0000000000003135.

3. Kamhieh Y, Fox H. Tranexamic acid in epistaxis: a systematic review. Clin Otolaryngol 2016; 41 (6): 771-6. doi. 10.1111/ coa.12645.

4. Glikson E, Chavkin U, Madgar O, Sagiv D, et al. Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents. Laryngoscope 2019; 129 (1): 119-23. doi. 10.1002/lary.27400.

5. Corte FC, Orfao T, Dias CC, Moura CP, et al. Risk factors for the occurrence of epistaxis: Prospective study. Auris Nasus Larynx 2018; 45 (3): 471-5. doi. 10.1016/j.anl.2017.07.021.

6. Zhou AH, Chung SY, Sylvester MJ, Zaki M, et al. To pack or not to pack: Inpatient management of epistaxis in the elderly. Am J Rhinol Allergy 2018; 32 (6): 539-45. doi. 10.1177/1945892418801259.

7. Chaaban MR, Zhang D, Resto V, Goodwin JS. Demographic, seasonal, and geographic differences in emergency department visits for epistaxis. Otolaryngol Head Neck Surg 2017; 156 (1): 81-6. doi. 10.1177/0194599816667295.

8. Sowerby LJ, DeSerres JJ, Rudmik L, Wright ED. Role of season, temperature and humidity on the incidence of epistaxis in Alberta, Canada. J Otolaryngol Head Neck Surg 2014; 43 (1): 10. doi. 10.1186/1916-0216-43-10.

9. Douglas CM, Tikka T, Broadbent B, Calder N, et al. Patterns of hospital admission in 54 501 patients with epistaxis over a 20-year period in Scotland, UK. Clin Otolaryngol 2018; 43 (6): 1465-70. doi. 10.1111/coa.13178.

10. Beck R, Sorge M, Schneider A, Dietz A. Current approaches to epistaxis treatment in primary and secondary care. Dtsch Arztebl Int 2018; 115 (1-02): 12-22. doi. 10.3238/ arztebl.2018.0012.

11. Bui R, Doan N, Chaaban MR. Epidemiologic and outcome analysis of epistaxis in a tertiary care center emergency department. Am J Rhinol Allergy 2020; 34 (1): 100-7. doi. 10.1177/1945892419876740.

12. Stadler RR, Kindler R, Holzmann D, Soyka MB. The longterm fate of epistaxis patients with exposure to antithrombotic medication. Eur Arch Otorhinolaryngol 2016; 273 (9): 2561-7. doi. 10.1007/s00405-016-3913-9.

13. Cohen O, Shoffel-Havakuk H, Warman M, Tzelnick S, et al. Early and late recurrent epistaxis admissions: patterns of incidence and risk factors. Otolaryngol Head Neck Surg 2017; 157 (3): 424-31. doi. 10.1177/0194599817705619.

14. Bola S, Marsh R, Braggins S, Potter C, et al. Does the continuation of warfarin change management outcomes in epistaxis patients? J Laryngol Otol 2016; 130 (3): 256-60. doi. 10.1017/S0022215115003424.

15. Szyszkowicz M, Shutt R, Kousha T, Rowe BH. Air pollution and emergency department visits for epistaxis. Clin Otolaryngol 2014; 39 (6): 345-51. doi. 10.1111/coa.12296.

16. Chaaban MR, Zhang D, Resto V, Goodwin JS. Factors influencing recurrent emergency department visits for epistaxis in the elderly. Auris Nasus Larynx 2018; 45 (4): 760-4. doi. 10.1016/j.anl.2017.11.010.

17. Khan M, Conroy K, Ubayasiri K, Constable J, et al. Initial assessment in the management of adult epistaxis: systematic review. J Laryngol Otol 2017; 131 (12): 1035-55. doi. 10.1017/S0022215117002031.